Legend Biotech Corp business relationships
Companies named in Legend Biotech Corp’s 20-F filed 2026-03-10, and public companies whose annual reports name Legend Biotech Corp. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.2 / 10
- AI naming
- 51 / 100 Top 1% in its category
- Agent readiness
- 35 / 100
- AI adoption
- 0 / 100
Named in Legend Biotech Corp’s annual report 5
“In December 2017, the Company entered into a collaboration and license agreement (the "Janssen Agreement") with Janssen Biotech, Inc., a Johnson & Johnson company ("Janssen"), for the worldwide development and commercialization of cilta-cel.” SEC filing
“Under the Novartis License Agreement, Novartis has agreed to pay up to $1.01 billion in milestone payments upon achievement of specified clinical, regulatory and commercial milestones, as well as tiered royalties on net sales.” SEC filing
“• our ability to achieve specified milestones under our collaboration with Janssen Biotech, Inc., a Johnson & Johnson company ("Janssen") for cilta-cel or under other collaboration and license agreements we have entered into with other third parties;” SEC filing
“Even if we succeed in securing collaborators for the development and commercialization of our product candidates, such as the Janssen Agreement or the Novartis License” SEC filing
“commercial supply agreements for BCMA CAR-T product with Novartis Pharmaceuticals Corporation (the "Novartis Supply Agreements"), pursuant to which Novartis agreed to manufacture cilta-cel for our clinical and commercial use to supplement our existing manufacturing capabilities.” SEC filing
Companies whose annual reports name Legend Biotech Corp 2
“...ion with strategic partners including XARELTO, co-developed with Bayer HealthCare AG, IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company and CARVYKTI, licensed and developed in collaboration with Legend Biotech USA Inc. and Legend Biotech Ireland Limited.” SEC filing
“Autologous cell therapies directed at BCMA have been commercialized by Bristol-Myers Squibb Company (Abecma®) and Legend Biotech Corporation with their partner Johnson & Johnson (Carvykti®).” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.